Table 2. Effect of tofacitinib on transforming growth factor beta 1, matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1 and hydroxyproline levels.

	TGF-ip (pg/mg)	MMP (units/mL)	TIMP-1 (pg/mL)	OH-Proline (Multiple of the control)
	Mean±SD	Mean±SD	Mean±SD	Mean±SD
Control	23.4±2.6	12.9±2.6	860.5±23.3	0.91±0.13
25 nM	18.6±3.5*	11.3±2.8	840.2±21.9	0.91±0.13
50 nM	17.2±1.9*	10.8±1.9	800.0±20.3	0.85±0.08
100 nM	11.3±2.1**	4.2±1.1*	621.3±25.6*	0.61±0.07
200 nM	10.6±1.8**	3.8±0.9*	324.3±17.5**	0.52±0.05
400 nM	3.6±0.9f	3.6±0.6*	321.9±16.2**	0.48±0.03
800 nM	2.1±0.7f	1.2±0.4**	310.2±18.8**	0.12±0.02
TGF-b Transforming growth factor beta; MMP: Matrix metalloproteinase; TIMP-1: Tissue inhibitor of metalloproteinase-1; OH: Hydroxy; SD: Standard deviation; * p<0.05; ** p<0.05; f p<0.05.